CN102459339A - 药物制剂 - Google Patents

药物制剂 Download PDF

Info

Publication number
CN102459339A
CN102459339A CN2010800269107A CN201080026910A CN102459339A CN 102459339 A CN102459339 A CN 102459339A CN 2010800269107 A CN2010800269107 A CN 2010800269107A CN 201080026910 A CN201080026910 A CN 201080026910A CN 102459339 A CN102459339 A CN 102459339A
Authority
CN
China
Prior art keywords
cytokine
pharmaceutical prepn
prepn
influenza
aforementioned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800269107A
Other languages
English (en)
Chinese (zh)
Inventor
G·斯特洛夫
W·万德雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptcell Ltd
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0910754A external-priority patent/GB0910754D0/en
Priority claimed from GB0913956A external-priority patent/GB0913956D0/en
Priority claimed from GB0920790A external-priority patent/GB0920790D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of CN102459339A publication Critical patent/CN102459339A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800269107A 2009-06-22 2010-06-22 药物制剂 Pending CN102459339A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0910754A GB0910754D0 (en) 2009-06-22 2009-06-22 Pharmaceutical agent
GB0910754.1 2009-06-22
GB0913956A GB0913956D0 (en) 2009-08-10 2009-08-10 Pharmaceutical agent
GB0913956.9 2009-08-10
GB0920790A GB0920790D0 (en) 2009-11-27 2009-11-27 Pharmaceutical agent
GB0920790.3 2009-11-27
PCT/EP2010/058788 WO2010149641A2 (en) 2009-06-22 2010-06-22 Pharmaceutical agent

Publications (1)

Publication Number Publication Date
CN102459339A true CN102459339A (zh) 2012-05-16

Family

ID=42727542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800269107A Pending CN102459339A (zh) 2009-06-22 2010-06-22 药物制剂

Country Status (10)

Country Link
US (1) US20120100155A1 (enExample)
EP (1) EP2424893A2 (enExample)
JP (1) JP2012530755A (enExample)
KR (1) KR20120044937A (enExample)
CN (1) CN102459339A (enExample)
AU (1) AU2010264764A1 (enExample)
BR (1) BRPI1013525A2 (enExample)
CA (1) CA2764257A1 (enExample)
RU (1) RU2012101995A (enExample)
WO (1) WO2010149641A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111214495A (zh) * 2020-03-02 2020-06-02 广西医科大学第一附属医院 注射用母牛分枝杆菌在制备用于防治呼吸系rsv感染的药物中的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130245469A1 (en) * 2012-03-19 2013-09-19 Cardiomems, Inc. Pulmonary Arterial Hemodynamic Monitoring for Chronic Obstructive Pulmonary Disease Assessment and Treatment
DE202013011988U1 (de) 2012-05-15 2015-04-01 Rajesh Shah Entzündungshemmende Rezeptur
WO2014081958A1 (en) 2012-11-21 2014-05-30 Cardiomems, Inc. Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment
WO2014145712A1 (en) 2013-03-15 2014-09-18 Cardiomems, Inc. Methods for the treatment of cardiovascular conditions
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044263A2 (en) * 2004-10-12 2006-04-27 Advanced Biotherapy, Inc. Treatment of herpes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2332236C1 (ru) * 2007-02-02 2008-08-27 Олег Ильич Эпштейн Лекарственное средство для лечения гриппа у птиц
US9598488B2 (en) * 2008-02-01 2017-03-21 Albany Medical College Blockage of interferon-gamma for prevention of polymicrobial synergy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044263A2 (en) * 2004-10-12 2006-04-27 Advanced Biotherapy, Inc. Treatment of herpes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N BAUMGARTH, A KELSO: "In vivo blockade of gamma interferon affects the influenza virus-induced humoral and the local cellular immune response in lung tissue", 《JOURNAL OF VIROLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111214495A (zh) * 2020-03-02 2020-06-02 广西医科大学第一附属医院 注射用母牛分枝杆菌在制备用于防治呼吸系rsv感染的药物中的应用

Also Published As

Publication number Publication date
BRPI1013525A2 (pt) 2016-04-05
RU2012101995A (ru) 2013-07-27
AU2010264764A1 (en) 2011-12-08
US20120100155A1 (en) 2012-04-26
WO2010149641A2 (en) 2010-12-29
CA2764257A1 (en) 2010-12-29
KR20120044937A (ko) 2012-05-08
EP2424893A2 (en) 2012-03-07
JP2012530755A (ja) 2012-12-06
WO2010149641A3 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
CA2496834C (en) Method of treatment of asthma using antibodies to complement component c5
Geng et al. Biologic therapies for allergic rhinitis and nasal polyposis
Holgate A look at the pathogenesis of asthma: the need for a change in direction
JP2009528264A (ja) Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法
JP2010539243A (ja) 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤
US20120100155A1 (en) Pharmaceutical agent
CN105073110A (zh) 通过诱导分化成调节性t细胞和促进调节性t细胞增殖来抑制免疫应答的药物组合物
Ramalingam et al. Regulation of helminth-induced Th2 responses by thymic stromal lymphopoietin
JP2008528650A (ja) ゾレア／オマリズマブ／ｅ２５と免疫抑制剤の相乗的組み合わせ剤
US9855229B2 (en) Treatment of respiratory disorders using ROR-gamma inhibitors
Gubernatorova et al. Mouse models of severe asthma for evaluation of therapeutic cytokine targeting
EP2744512B1 (en) Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
Padayachee et al. The nose as a route for therapy. Part 2 immunotherapy
US20210379175A1 (en) Pharmaceutical composition comprising attenuated streptococcus pneumoniae strains and use thereof
JP2006199614A (ja) Ｔｈ１型アレルギー疾患治療用組成物
KR20030062137A (ko) 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
KR101215709B1 (ko) 난백알부민을 유효성분으로 포함하는 알레르기 질환 예방 또는 치료용 조성물
WO2022011436A1 (en) Methods of treating coronavirus infection with bovine-hyperimmune colostrum
HRP20040071A2 (en) Use of il-18 inhibitors in hypersensitivity disorders
JP2018118960A (ja) １型糖尿病の予防又は治療剤
JP7337389B2 (ja) ヒアルロン酸を有効成分として含むアレルゲン作用増強剤
Mathias Respiratory Disorders of the Immune System and Their Pharmacological Treatment
Lam et al. SM17, an anti-IL-17RB antibody, ameliorates pathogenesis of CRSwNP and IPF via Th2/Th17 dual modulation
KR101844828B1 (ko) 시남알데하이드 유도체를 포함하는 비만 세포 활성화 억제용 조성물
Singh The impact of the dose and timing of epicutaneous allergen exposure on the manifestation of allergic responses in vivo

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120516